Work

Solution-based studies on the contact between the complement receptor 3 ligand-binding domain and simvastatin

Year: 2025

Type: article

Abstract: Simvastatin is a primary cholesterol-lowering medication, but it has also been reported to possess anti-inflammatory properties. Notably, the CD18 integrins are targets for simvastatin antagonism of ligand binding, which may affect leukocyte adhesion and diapedesis. Lymphocyte-associated antigen (LFA)-1 is inhibited through an allosteric mechanism by binding the lactone form of simvastatin (simvastatin-lac) to a hydrophobic pocket in the major ligand binding domain, the alpha chain I domain. By contrast, crystallographic evidence showed that complement receptor 3 (CR3) is inhibited by simvastatin in its carboxylate form (simvastatin-carbox) chelated by an Mg 2+ ion in the α M I metal ion-dependent adhesion site (MIDAS). We now report that the affinity ( K D ) of simvastatin-carbox for the α M I is ~650 μM, which is significantly weaker than the 50 %-inhibitory concentration of simvastatin-lac at 50 μM. The simvastatin-carbox was incapable of inhibiting CR3 binding to iC3b, nor did it exert any neuroprotective or anti-inflammatory effects in the middle cerebral artery occlusion animal model of stroke, unlike what has been reported for simvastatin-lac. From available structural data on the CR3 ligand binding domain in complex with C3d, we suggest that simvastatin-lac makes a critical ternary complex with the ligand binding domain and its ligand before engaging, in its carboxylate form, the MIDAS. In this way, both the LFA-1 and CR3 are antagonized by simvastatin-lac but through fundamentally different mechanisms.

Source: Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics

DOI: 10.1016/j.bbapap.2025.141096